Digestery
Longevity supplements › Resveratrol and Aging › Studies

Trial, not randomized · measured lab tests or safety

Trial in 10 adults with heart artery disease found mixed results for resveratrol

Diaz and colleagues · Scandinavian cardiovascular journal : SCJ · 2020

Original title: Acute resveratrol supplementation in coronary artery disease: towards patient stratification.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

Blood vessel widening (FMD) improved after bypass surgery (-1.4 vs. 5.0%; p = .004) but not after stent procedures (4.2 vs. -0.2%; NS). Authors say it impaired FMD in the stent group.

The study at a glance

Type of study
Trial, not randomized
Who or what was studied
10 people · Older adults (average age 66.6) with heart artery disease
What was tested
Resveratrol 330 mg three times a day for 3 days plus one more dose on day 4, vs placebo, in a crossover
What it measured
Lab tests or markers
Daily amount
990 mg a day
How long
1 week
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Scandinavian cardiovascular journal : SCJ, 2020
Source
PubMed record 31429599. This page is based on the abstract only.

How much this study counts

  • –Not randomized: the groups may differ in ways that affect the result.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 10 people. Small trials can miss real effects or find chance ones.
  • –Short: 1 week. Longer-term effects are unknown.
  • –Measured lab tests or markers, which stand in for aging and age-related disease. A better marker does not always mean better health.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    3

    1 benefit, 1 mixed, 1 harm

  3. Trials in people: lab tests or safety

    7

    4 benefit, 2 mixed, 1 no difference

    ↑ This study is the ringed dot

  4. Population studies

    1

    1 benefit

  5. Blood levels and genes

    1

    1 no difference

  6. Animals

    1

    1 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does resveratrol slow aging?”

Not shown in people.

Confidence: very low. Based on 22 on-topic papers.

Read the full answer

Of the other 6 papers on the same step: 4 benefit, 1 mixed, 1 no difference. This one found mixed. It differs from most of them.

Other papers on the same step

See all 22 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.